Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz US has entered into a settlement agreement with the class of end payer plaintiffs for USD 275 million Provision of USD 265 million taken to cover potential additional settlement costs with regard to the US generic drug industry antitrust litigation No impact on [...]
Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) One of several biosimilar value drivers for Sandoz Sandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadership Basel, November 15, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degeneration Further enhances leading US ophthalmology portfolio and increases access for patients Expected to be key biosimilar growth driver in US Basel, August 12, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net sales[1] of USD 2.6 billion, up 9% in constant currencies (up 7% in USD) Half-year net sales of USD 5.0 billion, up 7% in constant currencies [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across Europe, starting today, strengthens well-established Sandoz immunology portfolio in Europe, leveraging existing footprint Pyzchiva® first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including 130mg vial initiation [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® (ustekinumab-ttwe) is approved by FDA for all indications of reference medicine FDA granted provisional determination for interchangeability designation for Pyzchiva® Extends Sandoz immunology portfolio and further strengthens biosimilar position Expected to be among first wave of ustekinumab biosimilars to launch in US [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and quality Approved for treatment of cancer-related [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD) Biosimilar business growing 21% in constant currencies All regions contributing to growth Acquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024 Basel, May 7, 2024 [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost® on May 31, 2025 or earlier under certain circumstances Jubbonti® and Wyost® are first and only FDA-approved biosimilars to and interchangeable with Prolia*® and [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in Europe EC approval based on robust development program confirming match to reference medicine in terms of safety, efficacy and quality Sandoz remains committed to accelerating access to potentially life-changing treatments and continues strengthening immunology portfolio [...]